Granulomatosis eosinofílica con poliangitis (GEPA). Jueves 3 de septiembre

De

 Granulomatosis eosinofílica con poliangitis (GEPA)



Dra. Natalia Aguirre 

Comentarios

  1. Valeria Zapata Marín3 de septiembre de 2020 a las 15:35

    En los pacientes con sospecha de EGPA, surge una duda y es cómo clasificar a los pacientes con asma y eosinofilia sanguínea, pero sin evidencia definitiva de vasculitis fuera de los pulmones, la nariz y los senos nasales. Una propuesta es que estos pacientes deben cumplir además uno de los siguientes:

    ●Poliangeítis definida: biopsia que muestra vasculitis necrotizante, biopsia que muestra glomerulonefritis necrosante o semilunar, hemorragia alveolar, púrpura palpable o infarto de miocardio debido a coronaritis comprobada.

    ●Supuestos definitivos de la vasculitis: hematuria asociada con cilindros de glóbulos rojos > 10% de eritrocitos dismórficos; hematuria con proteinuria 2+; vasculitis leucocitoclástica / infiltración eosinofílica de una pared arterial en la biopsia

    ●Mononeuritis o mononeuritis múltiple

    ●Anticuerpos anticitoplasma de neutrófilos (ANCA) y manifestaciones sistémicas (p. Ej., Miocarditis, pericarditis, neuropatía periférica, otras enfermedades renales, dolor abdominal)

    En los pacientes que no cumplen con uno de los anteriores, surge una propuesta y es la creación de una categoría denominada “asma hipereosinofílica con manifestaciones sistémicas” para pacientes con asma, hipereosinofilia (≥1500 células / microL y / o ≥10 por ciento de leucocitos), y cualquier manifestación sistémica, pero sin ANCA, poliangeítis definida, una sustituto de poliangeítis o mononeuritis.

    ResponderEliminar

Publicar un comentario

Entradas populares de este blog

Future perspectives of anticholinergics for the treatment of asthma in adults and children. Viernes 4 de octubre

De
Future perspectives of anticholinergics for the treatment of asthma in adults and children. Authors : Buhl R1, Hamelmann E2,3. 1 Pulmonary Department, Johannes Gutenberg University Hospital Mainz, Mainz, Germany, roland.buhl@unimedizin-mainz.de. 2 Children's Center Bethel, Evangelic Hospital Bethel, Department of Pediatrics, Bielefeld, Germany. 3 University Children's Hospital, Allergy Center Ruhr, Ruhr University Bochum, Bochum, Germany. Abstract Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma (GINA) strategy and is based on a backbone of inhaled corticosteroid (ICS) therapy with the use of additional therapies to achieve disease control. Inhaled long-acting bronchodilators alone and in combination are the preferred add-on treatment options. Although long-ac...
Leer más

ACE Inhibitor-Mediated Angioedema. Martes 17 de marzo

De
ACE Inhibitor-Mediated Angioedema Authors: Vincenzo Montinaro  1 , Marco Cicardi  2 Abstract Angioedema (AE) occurring during ACE inhibitor therapy (ACEi-AE) is a rare complication involving between 0.1 and 0.7% of treated patients. AE can also complicate other therapeutic regimens that block the renin-angiotensin aldosterone system. Other drugs, such as immune suppressors, some type of antidiabetics or calcium antagonists, can increase the likelihood of ACEi-AE when associated to ACEi. There is a clear ethnic predisposition, since African-Americans or Hispanics show a higher prevalence of this condition compared to Caucasians. At least in African-Americans the genetic predisposition accounts for a general higher prevalence of AE, independently from the cause. People that experience ACEi-AE may have some recurrence when they are switched to an angiotensin-receptor blocker (ARB); however, epidemiological studies on large cohorts have shown that angiotensin receptor bloc...
Leer más

ICON: Diagnosis and management of allergic conjunctivitis. Miércoles 25 de marzo

De
ICON: Diagnosis and management of allergic conjunctivitis. Authors: Bielory L1, Delgado L2, Katelaris CH3, Leonardi A4, Rosario N5, Vichyanoud P6. Author information Abstract Ocular allergy (OA), interchangeably known as allergic conjunctivitis, is a common immunological hypersensitivity disorder affecting up to 40% of the population. Ocular allergy has been increasing in frequency, with symptoms of itching, redness, and swelling that significantly impacts an individual's quality of life (QOL). Ocular allergy is an often underdiagnosed and undertreated health problem, because only 10% of patients with OA symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary nonpharmacological remedies. The clinical course, duration, severity, and co-morbidities are varied and depend, in part, on the specific ocular tissues that are affected and on immunologic mechanism(s) involved, both local and systemic. It is frequently associat...
Leer más